Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle

European Journal of Sport Science

Volumn 16, Issue 7, 2016, Pages 801-807

  Søndergård, Stine D ^a   Dela, Flemming ^a   Helge, Jørn W ^a   Larsen, Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Actovegin; human skeletal muscle; mitochondrial oxidative capacity; non prohibited drug

Indexed keywords

ACTOVEGIN; HEME;

ADULT; ANALOGS AND DERIVATIVES; BREATHING; DOPING; DRUG EFFECTS; HUMAN; METABOLISM; MIDDLE AGED; MUSCLE MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; SKELETAL MUSCLE;

ADULT; DOPING IN SPORTS; HEME; HUMANS; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; OXIDATIVE PHOSPHORYLATION; RESPIRATION;

EID: 84953721162     PISSN: 17461391     EISSN: 15367290     Source Type: Journal    
DOI: 10.1080/17461391.2015.1130750     Document Type: Article

References (36)

1. A.K.Appiah, (2002). Treatment of severe primary postpartum hemorrhage with a deproteinized hemodialysate. International Journal of Gynaecology and Obstetrics, 76(1), 75–76. doi:10.1016/S0020-7292(01)00532-X
2. F.S.Apple, & M.A.Rogers, (1986). Mitochondrial creatine kinase activity alterations in skeletal muscle during long-distance running. Journal of Applied Physiology (1985), 61(2), 482–485.
3. R.Boushel, E.Gnaiger, J.A.Calbet, J.Gonzalez-Alonso, C.Wright-Paradis, H.Sondergaard,.. B.Saltin, (2011). Muscle mitochondrial capacity exceeds maximal oxygen delivery in humans. Mitochondrion, 11(2), 303–307. doi:10.1016/j.mito.2010.12.006
4. F.Buchmayer, J.Pleiner, M.W.Elmlinger, G.Lauer, G.Nell, & H.H.Sitte, (2011). Actovegin(R):A biological drug for more than 5 decades. Wiener medizinische Wochenschrift, 161(3–4), 80–88. doi:10.1007/s10354-011-0865-y
5. E.F.Coyle, (1992). Carbohydrate supplementation during exercise. Journal of Nutrition, 122(Suppl. 3), 788–795.
6. E.A.Derev'yannykh, G.N.Bel'skaya, E.A.Knoll, L.G.Krylova, & D.V.Popov, (2008). Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neuroscience and Behavioral Physiology, 38(8), 873–875. doi:10.1007/s11055-008-9051-0
7. P.P.Dzeja, R.J.Zeleznikar, & N.D.Goldberg, (1998). Adenylate kinase:Kinetic behavior in intact cells indicates it is integral to multiple cellular processes. Molecular and Cellular Biochemistry, 184(1–2), 169–182. doi:10.1023/A:1006859632730
8. A.Guadalupe-Grau, U.Plenge, S.Helbo, M.Kristensen, P.R.Andersen, A.Fago,.. J.W.Helge, (2014). Effects of an 8-weeks erythropoietin treatment on mitochondrial and whole body fat oxidation capacity during exercise in healthy males. Journal of Sports Science, 1–9. doi:10.1080/02640414.2014.951872
9. J.O.Holloszy, (1967). Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. Journal of Biological Chemistry, 242(9), 2278–2282.
10. S.Jacob, G.J.Dietze, F.Machicao, G.Kuntz, & H.J.Augustin, (1996). Improvement of glucose metabolism in patients with type II diabetes after treatment with a hemodialysate. Arzneimittelforschung, 46(3), 269–272.
11. R.A.Jacobs, D.Fluck, T.C.Bonne, S.Burgi, P.M.Christensen, M.Toigo, & C.Lundby, (2013). Improvements in exercise performance with high-intensity interval training coincide with an increase in skeletal muscle mitochondrial content and function. Journal of Applied Physiology (1985), 115(6), 785–793. doi:10.1152/japplphysiol.00445.2013
12. R.A.Jacobs, P.Rasmussen, C.Siebenmann, V.Diaz, M.Gassmann, D.Pesta, … C.Lundby, (2011). Determinants of time trial performance and maximal incremental exercise in highly trained endurance athletes. Journal of Applied Physiology (1985), 111(5), 1422–1430. doi:10.1152/japplphysiol.00625.2011
13. S.Kanowski, E.Kinzler, E.Lehmann, A.Schweizer, & G.Kuntz, (1995). Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry, 28(4), 125–133. doi:10.1055/s-2007-979604
14. M.Kellerer, F.Machicao, L.Berti, B.Sixt, J.Mushack, E.Seffer,.. H.U.Haring, (1993). Inositol phospho-oligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. Biochemical Journal, 295(Pt 3), 699–704. doi:10.1042/bj2950699
15. S.Kristiansen, J.Gade, J.F.Wojtaszewski, B.Kiens, & E.A.Richter, (2000). Glucose uptake is increased in trained vs. untrained muscle during heavy exercise. Journal of Applied Physiology (1985), 89(3), 1151–1158.
16. T.Kuninaka, Y.Senga, H.Senga, & M.Weiner, (1991). Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. Journal of Cellular Physiology, 146(1), 148–155. doi:10.1002/jcp.1041460119
17. S.Larsen, J.H.Danielsen, S.D.Sondergard, D.Sogaard, A.Vigelsoe, R.Dybboe,.. J.W.Helge, (2015). The effect of high-intensity training on mitochondrial fat oxidation in skeletal muscle and subcutaneous adipose tissue. Scandinavian Journal of Medicine & Science in Sports, 25(1), 59–69. doi:10.1111/sms.12252
18. S.Larsen, J.Nielsen, C.N.Hansen, L.B.Nielsen, F.Wibrand, N.Stride,.. M.Hey-Mogensen, (2012). Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. Journal of Physiology, 590(Pt 14), 3349–3360. doi:10.1113/jphysiol.2012.230185
19. S.Larsen, N.Stride, M.Hey-Mogensen, C.N.Hansen, J.L.Andersen, S.Madsbad,.. F.Dela, (2011). Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes. Diabetologia, 54(6), 1427–1436. doi:10.1007/s00125-011-2098-4
20. P.Lee, L.Nokes, & P.M.Smith, (2012). No effect of intravenous Actovegin(R) on peak aerobic capacity. International Journal of Sports Medicine, 33(4), 305–309. doi:10.1055/s-0031-1291322
21. P.Lee, A.Rattenberry, S.Connelly, & L.Nokes, (2011). Our experience on Actovegin, is it cutting edge? International Journal of Sports Medicine, 32(4), 237–241. doi:10.1055/s-0030-1269862
22. F.Machicao, D.F.Muresanu, H.Hundsberger, M.Pfluger, & A.Guekht, (2012). Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. Journal of Neurological Sciences, 322(1–2), 222–227. doi:10.1016/j.jns.2012.07.069
23. F.Machicao, J.Mushack, E.Seffer, B.Ermel, & H.U.Haring, (1990). Mannose, glucosamine and inositol monophosphate inhibit the effects of insulin on lipogenesis. Further evidence for a role for inositol phosphate-oligosaccharides in insulin action. Biochemical Journal, 266(3), 909–916.
24. B.Obermaier-Kusser, C.Muhlbacher, J.Mushack, E.Seffer, B.Ermel, F.Machicao,.. H.U.Haring, (1989). Further evidence for a two-step model of glucose-transport regulation. Inositol phosphate-oligosaccharides regulate glucose-carrier activity. Biochemical Journal, 261(3), 699–705. doi:10.1042/bj2610699
25. J.W.Orchard, T.M.Best, H.W.Mueller-Wohlfahrt, G.Hunter, B.H.Hamilton, N.Webborn,.. P.Glasgow, (2008). The early management of muscle strains in the elite athlete:Best practice in a world with a limited evidence basis. British Journal of Sports Medicine, 42(3), 158–159. doi:10.1136/bjsm.2008.046722
26. C.G.Perry, D.A.Kane, E.A.Herbst, K.Mukai, D.S.Lark, D.C.Wright,.. G.P.Holloway, (2012). Mitochondrial creatine kinase activity and phosphate shuttling are acutely regulated by exercise in human skeletal muscle. Journal of Physiology, 590(Pt 21), 5475–5486. doi:10.1113/jphysiol.2012.234682
27. D.Pesta, & E.Gnaiger, (2012). High-resolution respirometry:OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods in Molecular Biology, 810, 25–58. doi:10.1007/978-1-61779-382-0_3
28. U.Plenge, B.Belhage, A.Guadalupe-Grau, P.R.Andersen, C.Lundby, F.Dela,.. R.Boushel, (2012). Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Frontiers in Physiology, 3, article id 50, 1–5. doi:10.3389/fphys.2012.00050
29. H.Reichel, C.Weiss, & H.P.Leichtweiss, (1965). The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneimittelforschung, 15(7), 756–757.
30. G.Schafer, & W.Lamprecht, (1965). The effects of blood extracts on mitochondrial respiration and oxidative phosphorylation. Arzneimittelforschung, 15(7), 757–759.
31. I.Skoog, A.D.Korczyn, & A.Guekht, (2012). Neuroprotection in vascular dementia:A future path. Journal of Neurological Sciences, 322(1–2), 232–236. doi:10.1016/j.jns.2012.02.013
32. M.Tonkonogi, B.Walsh, M.Svensson, & K.Sahlin, (2000). Mitochondrial function and antioxidative defence in human muscle:Effects of endurance training and oxidative stress. Journal of Physiology, 528(Pt 2), 379–388. doi:10.1111/j.1469-7793.2000.00379.x
33. C.Tsitsimpikou, A.Tsiokanos, K.Tsarouhas, P.Schamasch, K.D.Fitch, D.Valasiadis, & A.Jamurtas, (2009). Medication use by athletes at the Athens 2004 Summer Olympic Games. Clinical Journal of Sport Medicine, 19(1), 33–38. doi:10.1097/JSM.0b013e31818f169e
34. United States Anti-Doping Agency. (2012). Reasoned decision of the United States Anti-doping Agency on disqualification and ineligibility:United States anti-doping agency, claimant, v. Lance Armstrong, Respondent. Retrieved from http://d3epuodzu3wuis.cloudfront.net/ReasonedDecision.pdf
35. B.Walsh, M.Tonkonogi, & K.Sahlin, (2001). Effect of endurance training on oxidative and antioxidative function in human permeabilized muscle fibres. Pflugers Archiv, 442(3), 420–425. doi:10.1007/s004240100538
36. D.Ziegler, L.Movsesyan, B.Mankovsky, I.Gurieva, Z.Abylaiuly, & I.Strokov, (2009). Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care, 32(8), 1479–1484. doi:10.2337/dc09-0545